Skip NavigationSkip to Content

A germline 1;3 translocation disrupting the VHL gene: a novel genetic cause for von Hippel-Lindau

  1. Author:
    Ricketts, Christopher J
    Vocke, Cathy D [ORCID]
    Lang, Martin
    Chen,Jack
    Zhao,Yongmei
    Tran,Bao
    Tandon, Mayank
    Schmidt, Laura S
    Ball, Mark W
    Linehan, W Marston [ORCID]
  2. Author Address

    Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Rockville, Maryland, USA., Urologic Oncology Branch, National Cancer Institue, Bethesda, Maryland, USA., CCR Sequencing Facility, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA., CCR Collaborative Bioinformatics Resource, National Cancer Institute, Bethesda, Maryland, USA., Basic Science Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA., Urologic Oncology Branch, National Cancer Institue, Bethesda, Maryland, USA WML@nih.gov.,
    1. Year: 2022
    2. Date: Jan
    3. Epub Date: 2020 10 16
  1. Journal: Journal of Medical Genetics
    1. 59
    2. 1
    3. Pages: 18-22
  2. Type of Article: Article
  3. ISSN: 0022-2593
  1. Abstract:

    Von Hippel-Lindau (VHL) disease is an autosomal dominant hereditary tumour susceptibility disease caused by germline pathogenic variation of the VHL tumour suppressor gene. Affected individuals are at risk of developing multiple malignant and benign tumours in a number of organs.In this report, a male patient in his 20s who presented to the Urologic Oncology Branch at the National Cancer Institute with a clinical diagnosis of VHL was found to have multiple cerebellar haemangioblastomas, bilateral epididymal cysts, multiple pancreatic cysts, and multiple, bilateral renal tumours and cysts. The patient had no family history of VHL and was negative for germline VHL mutation by standard genetic testing. Further genetic analysis demonstrated a germline balanced translocation between chromosomes 1 and 3, t(1;3)(p36.3;p25) with a breakpoint on chromosome 3 within the second intron of the VHL gene. This created a pathogenic germline alteration in VHL by a novel mechanism that was not detectable by standard genetic testing.Karyotype analysis is not commonly performed in existing genetic screening protocols for patients with VHL. Based on this case, protocols should be updated to include karyotype analysis in patients who are clinically diagnosed with VHL but demonstrate no detectable mutation by existing genetic testing. © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

    See More

External Sources

  1. DOI: 10.1136/jmedgenet-2020-107308
  2. PMID: 33067352
  3. WOS: 000731964400003
  4. PII : jmedgenet-2020-107308

Library Notes

  1. Fiscal Year: FY2020-2021
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel